Amedisys (AMED)
(Delayed Data from NSDQ)
$91.79 USD
+0.63 (0.69%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $91.80 +0.01 (0.01%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth C Momentum B VGM
Price, Consensus and EPS Surprise
AMED 91.79 +0.63(0.69%)
Will AMED be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for AMED based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AMED
Compared to Estimates, Amedisys (AMED) Q1 Earnings: A Look at Key Metrics
Amedisys (AMED) Q1 Earnings and Revenues Surpass Estimates
AMED: What are Zacks experts saying now?
Zacks Private Portfolio Services
Premium Growth Propels Humana (HUM) to Easy Q1 Earnings Beat
Amedisys (AMED) Earnings Expected to Grow: What to Know Ahead of Q1 Release
Here's Why Amedisys (AMED) is a Strong Value Stock
Other News for AMED
Analysts Offer Insights on Healthcare Companies: Amedisys (AMED) and Gilead Sciences (GILD)
Truist Financial Reaffirms Their Hold Rating on Amedisys (AMED)
Amedisys: Q1 Earnings Snapshot
Amedisys Reports First Quarter 2024 Financial Results
AMED Stock Earnings: Amedisys Beats EPS, Beats Revenue for Q1 2024